TITLE

Everolimus Tablets (Zortress)

AUTHOR(S)
Elliott, William T.; Chan, James
PUB. DATE
July 2010
SOURCE
Internal Medicine Alert;7/29/2010, Vol. 32 Issue 14, p110
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article describes the Everolimus Tablets, a rapamycin inhibitor, which has been approved by the U.S. Food and Drug Administration.
ACCESSION #
53269508

 

Related Articles

  • Pharmacological Retention of Oral Mucosa Progenitor/Stem Cells. Izumi, K.; Inoki, K.; Fujimori, Y.; Marcelo, C. L.; Feinberg, S. E. // Journal of Dental Research;Dec2009, Vol. 88 Issue 12, p1113 

    Oral mucosa progenitor/stem cells reside as a small-sized cell population that eventually differentiates concurrently with an increase in cell size. Activation of the mammalian target of rapamycin (mTOR) leads to an increase in cell size. We hypothesized that rapamycin, a specific inhibitor of...

  • Actavis wins FDA approval for anxiety disorder drug.  // PharmaWatch: Biotechnology;May2010, Vol. 9 Issue 5, p13 

    The article reports on the approval of Actavis Group hf.'s Alprazolam orally disintegrating tablets (ODT) in managing anxiety disorder by the U.S. Food & Drug Administration.

  • New molecular entities/new biologics.  // Formulary;Jan2002, Vol. 37 Issue 1, p6 

    Presents several drugs approved by the United States Food and Drug Administration. Valdecoxib tablets; Ertapenem for injection; Dexmethylphenidate HCI tablets.

  • New formulations/combinations.  // Formulary;Jan2002, Vol. 37 Issue 1, p10 

    Presents the approval of the formulation of dexmethylphenidate HCI tablets and norelgestromin or ethinyl estradiol transdermal system by the United States Food and Drug Administration. Dosage of the drugs; Prices of the drugs; Warnings and contraindications of the drugs.

  • First extended-cycle contraceptive approved.  // Drug Topics;9/15/2003, Vol. 147 Issue 18, p8 

    Reports on the United States Food and Drug Administration's approval of levonorgestrel/ethinyl estradiol tablets for the prevention of pregnancy.

  • Opioid-Ibuprofen Tablet for Acute Pain.  // American Family Physician;1/15/1998, Vol. 57 Issue 2, p376 

    Announces that the first opioid-ibuprofen combination tablet has been approved by the United States Food & Drug Administration for the treatment of acute pain. Components of the tablet; Results of clinical trials on the drug.

  • FDA Clears New Products for Market.  // Chain Drug Review;1/21/2013, Vol. 35 Issue 2, p38 

    The article informs that the U.S. Food and Drug Administration has approved Mylan Pharmaceuticals Inc.'s orally disintegrating tablets containing rizatriptan benzoate.

  • Ulcer, Pain, Hypertension Drugs OK'd.  // Chain Drug Review;11/21/2011, Vol. 33 Issue 20, p67 

    The article reports that the Abbreviated New Drug Application (ANDA) for glycopyrrolate tablets U.S. Pharmcaopeia (USP) from Boca Pharmacal Inc. received approval from the U.S. Food and Drug Administration.

  • Expanded approval for Glaxo's Lamictal.  // PharmaWatch: CNS;March 2004, Vol. 3 Issue 3, p17 

    Reports that the U.S. Food and Drug Administration (FDA) has approved GlaxoSmithKline PLC's Lamictal tablet for use as monotherapy for treatment of partial seizures. Indication of Lamictal approved by the FDA; Approval for maintenance treatment; Terms of the FDA approval.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics